148 related articles for article (PubMed ID: 21166702)
1. Ribonucleotide reductase M2 subunit is a novel diagnostic marker and a potential therapeutic target in bladder cancer.
Morikawa T; Maeda D; Kume H; Homma Y; Fukayama M
Histopathology; 2010 Dec; 57(6):885-92. PubMed ID: 21166702
[TBL] [Abstract][Full Text] [Related]
2. Expression of ribonucleotide reductase M2 subunit in gastric cancer and effects of RRM2 inhibition in vitro.
Morikawa T; Hino R; Uozaki H; Maeda D; Ushiku T; Shinozaki A; Sakatani T; Fukayama M
Hum Pathol; 2010 Dec; 41(12):1742-8. PubMed ID: 20825972
[TBL] [Abstract][Full Text] [Related]
3. Metastasis-suppressing potential of ribonucleotide reductase small subunit p53R2 in human cancer cells.
Liu X; Zhou B; Xue L; Shih J; Tye K; Lin W; Qi C; Chu P; Un F; Wen W; Yen Y
Clin Cancer Res; 2006 Nov; 12(21):6337-44. PubMed ID: 17085643
[TBL] [Abstract][Full Text] [Related]
4. Ribonucleotide reductase subunits M2 and p53R2 are potential biomarkers for metastasis of colon cancer.
Liu X; Zhou B; Xue L; Yen F; Chu P; Un F; Yen Y
Clin Colorectal Cancer; 2007 Jan; 6(5):374-81. PubMed ID: 17311703
[TBL] [Abstract][Full Text] [Related]
5. Potent siRNA inhibitors of ribonucleotide reductase subunit RRM2 reduce cell proliferation in vitro and in vivo.
Heidel JD; Liu JY; Yen Y; Zhou B; Heale BS; Rossi JJ; Bartlett DW; Davis ME
Clin Cancer Res; 2007 Apr; 13(7):2207-15. PubMed ID: 17404105
[TBL] [Abstract][Full Text] [Related]
6. The prognostic value of ribonucleotide reductase small subunit M2 in predicting recurrence for prostate cancers.
Huang Y; Liu X; Wang YH; Yeh SD; Chen CL; Nelson RA; Chu P; Wilson T; Yen Y
Urol Oncol; 2014 Jan; 32(1):51.e9-19. PubMed ID: 24360663
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of catalytic subunit M2 in patients with ovarian cancer.
Wang LM; Lu FF; Zhang SY; Yao RY; Xing XM; Wei ZM
Chin Med J (Engl); 2012 Jun; 125(12):2151-6. PubMed ID: 22884145
[TBL] [Abstract][Full Text] [Related]
8. Ribonucleotide reductase M2 is a promising molecular target for the treatment of oral squamous cell carcinoma.
Iwamoto K; Nakashiro K; Tanaka H; Tokuzen N; Hamakawa H
Int J Oncol; 2015 May; 46(5):1971-7. PubMed ID: 25738429
[TBL] [Abstract][Full Text] [Related]
9. Gene expression profile in squamous cell carcinoma of the urinary bladder using complementary deoxyribonucleic acid microarray.
Ewis AA; El-Samman E; Ali N; Kajimoto K; Shinohara Y; Ishikawa M; Kanayama HO; Baba Y
Urol Oncol; 2007; 25(2):120-7. PubMed ID: 17349526
[TBL] [Abstract][Full Text] [Related]
10. Tumorigenic role of podoplanin in esophageal squamous-cell carcinoma.
Rahadiani N; Ikeda J; Makino T; Tian T; Qiu Y; Mamat S; Wang Y; Doki Y; Aozasa K; Morii E
Ann Surg Oncol; 2010 May; 17(5):1311-23. PubMed ID: 20066519
[TBL] [Abstract][Full Text] [Related]
11. Expression of caveolin-1 and caveolin-2 in urothelial carcinoma of the urinary bladder correlates with tumor grade and squamous differentiation.
Fong A; Garcia E; Gwynn L; Lisanti MP; Fazzari MJ; Li M
Am J Clin Pathol; 2003 Jul; 120(1):93-100. PubMed ID: 12866378
[TBL] [Abstract][Full Text] [Related]
12. E2F1 promote the aggressiveness of human colorectal cancer by activating the ribonucleotide reductase small subunit M2.
Fang Z; Gong C; Liu H; Zhang X; Mei L; Song M; Qiu L; Luo S; Zhu Z; Zhang R; Gu H; Chen X
Biochem Biophys Res Commun; 2015 Aug; 464(2):407-15. PubMed ID: 26093293
[TBL] [Abstract][Full Text] [Related]
13. Expression of cell cycle-related molecular markers in patients treated with radical cystectomy for squamous cell carcinoma of the bladder.
Youssef RF; Shariat SF; Kapur P; Kabbani W; Ghoneim T; King E; Cockburn A; Mosbah A; Abol-Enein H; Ghoneim M; Lotan Y
Hum Pathol; 2011 Mar; 42(3):347-55. PubMed ID: 21111452
[TBL] [Abstract][Full Text] [Related]
14. Targeting ribonucleotide reductase M2 subunit by small interfering RNA exerts anti-oncogenic effects in gastric adenocarcinoma.
Kang W; Tong JH; Chan AW; Zhao J; Wang S; Dong Y; Sin FM; Yeung S; Cheng AS; Yu J; To K
Oncol Rep; 2014 Jun; 31(6):2579-86. PubMed ID: 24756820
[TBL] [Abstract][Full Text] [Related]
15. Proteomics and immunohistochemistry define some of the steps involved in the squamous differentiation of the bladder transitional epithelium: a novel strategy for identifying metaplastic lesions.
Celis JE; Celis P; Ostergaard M; Basse B; Lauridsen JB; Ratz G; Rasmussen HH; Orntoft TF; Hein B; Wolf H; Celis A
Cancer Res; 1999 Jun; 59(12):3003-9. PubMed ID: 10383167
[TBL] [Abstract][Full Text] [Related]
16. Thyroid transcription factor 1 expression in small cell carcinoma of the urinary bladder: an immunohistochemical profile of 44 cases.
Jones TD; Kernek KM; Yang XJ; Lopez-Beltran A; MacLennan GT; Eble JN; Lin H; Pan CX; Tretiakova M; Baldridge LA; Cheng L
Hum Pathol; 2005 Jul; 36(7):718-23. PubMed ID: 16084939
[TBL] [Abstract][Full Text] [Related]
17. Small interfering RNA targeting heat shock protein 70 enhances chemosensitivity in human bladder cancer cells.
Behnsawy HM; Miyake H; Kusuda Y; Fujisawa M
Urol Oncol; 2013 Aug; 31(6):843-8. PubMed ID: 21889367
[TBL] [Abstract][Full Text] [Related]
18. Identificating 14-3-3 sigma as a lymph node metastasis-related protein in human lung squamous carcinoma.
Li DJ; Deng G; Xiao ZQ; Yao HX; Li C; Peng F; Li MY; Zhang PF; Chen YH; Chen ZC
Cancer Lett; 2009 Jun; 279(1):65-73. PubMed ID: 19231067
[TBL] [Abstract][Full Text] [Related]
19. CD24 expression is a novel prognostic factor in esophageal squamous cell carcinoma.
Sano A; Kato H; Sakurai S; Sakai M; Tanaka N; Inose T; Saito K; Sohda M; Nakajima M; Nakajima T; Kuwano H
Ann Surg Oncol; 2009 Feb; 16(2):506-14. PubMed ID: 19050962
[TBL] [Abstract][Full Text] [Related]
20. Expression of EphA2 and Ephrin A-1 in carcinoma of the urinary bladder.
Abraham S; Knapp DW; Cheng L; Snyder PW; Mittal SK; Bangari DS; Kinch M; Wu L; Dhariwal J; Mohammed SI
Clin Cancer Res; 2006 Jan; 12(2):353-60. PubMed ID: 16428472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
